BioMarin Buys ZyStor For $115M

Xconomy San Francisco — 

BioMarin Pharmaceutical (NASDAQ: BMRN), the Novato, CA-based maker of drugs for rare diseases, said it has agreed to acquire Milwaukee, WI-based ZyStor Therapeutics for $22 million upfront, plus another $93 million if certain milestones are met, bringing the total value of  the deal to $115 million. ZyStor is developing enzyme replacement therapies for lysosomal storage disorders. Its lead drug candidate is for the treatment of Pompe disease.

By posting a comment, you agree to our terms and conditions.

Comments are closed.